Home
REGN
REGN News

Latest Regeneron Pharmaceuticals Inc. (REGN) News on November 23, 2024

Regeneron Pharmaceuticals, Inc. (REGN): Among the Best Genomics Stocks to Buy Right Now

Insider Monkey

3 days ago

Regeneron Pharmaceuticals, Inc. (REGN): Among the Best Genomics Stocks to Buy Right Now

Here’s Why Regeneron Pharmaceuticals (REGN) Declined in Q3

Insider Monkey

4 days ago

Here’s Why Regeneron Pharmaceuticals (REGN) Declined in Q3

FDA Accepts SNY and REGN's Dupixent Re-Submitted sBLA for Urticaria

Zacks

5 days ago

FDA Accepts SNY and REGN's Dupixent Re-Submitted sBLA for Urticaria

MT Newswires

5 days ago

Deutsche Bank Cuts Regeneron Pharmaceuticals Price Target to $805 From $900, Maintains Hold Rating

Morningstar Research

5 days ago

Analyst Report: Regeneron Pharmaceuticals, Inc.

FDA reviews Sanofi and Regeneron’s Dupixent label expansion for urticaria

Pharmaceutical Technology

8 days ago

FDA reviews Sanofi and Regeneron’s Dupixent label expansion for urticaria

MT Newswires

8 days ago

Wolfe Initiates Regeneron Pharmaceuticals at Outperform With $1,150 Price Target

MT Newswires

8 days ago

Regeneron Pharmaceuticals, Sanofi Say FDA Accepts Application for Skin Disease Treatment

Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU)

GlobeNewswire

8 days ago

Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU)

Investing.com

9 days ago

Citi initiates coverage on 5 new biotech stocks

Argus Research

9 days ago

Daily Spotlight: Argus Raises EPS Forecasts

2 Top Growth Stocks to Buy on the Dip

Motley Fool

9 days ago

2 Top Growth Stocks to Buy on the Dip

Regeneron/Sanofi's Dupixent Approval Signals Major Treatment Breakthrough For Smokers' Lung Disease

Benzinga

10 days ago

Regeneron/Sanofi's Dupixent Approval Signals Major Treatment Breakthrough For Smokers' Lung Disease

Regeneron to Highlight Pioneering Pipeline Progress Across Multiple Modalities Spanning 10 Types of Blood Cancers and Disorders at ASH

GlobeNewswire

10 days ago

Regeneron to Highlight Pioneering Pipeline Progress Across Multiple Modalities Spanning 10 Types of Blood Cancers and Disorders at ASH

Regeneron Announces Investor Conference Presentations

GlobeNewswire

12 days ago

Regeneron Announces Investor Conference Presentations

MT Newswires

12 days ago

Argus Adjusts Price Target on Regeneron Pharmaceuticals to $1,000 From $1,175

Argus Research

12 days ago

Analyst Report: Regeneron Phars, Inc

Argus Research

12 days ago

Market Digest: EXPE, FCX, HOLX, MRO, NOC, REGN, GEN, WBA, ANET

We Think Regeneron Pharmaceuticals (NASDAQ:REGN) Can Manage Its Debt With Ease

Simply Wall St.

13 days ago

We Think Regeneron Pharmaceuticals (NASDAQ:REGN) Can Manage Its Debt With Ease

Morningstar Research

15 days ago

Analyst Report: Regeneron Pharmaceuticals, Inc.

Regeneron price target lowered to $1,000 from $1,150 at Oppenheimer

TipRanks

16 days ago

Regeneron price target lowered to $1,000 from $1,150 at Oppenheimer

EMA approves Sanofi/Regeneron’s Dupixent for young EoE patients

Pharmaceutical Technology

16 days ago

EMA approves Sanofi/Regeneron’s Dupixent for young EoE patients

MT Newswires

17 days ago

Oppenheimer Adjusts Regeneron Pharmaceuticals Price Target to $1,000 From $1,150, Maintains Outperform Rating

MT Newswires

17 days ago

Sanofi, Regeneron Receive European Pediatric Approval for Throat Disease Treatment

Is It Time to Buy October's Worst-Performing Nasdaq Stocks?

Motley Fool

17 days ago

Is It Time to Buy October's Worst-Performing Nasdaq Stocks?

Dupixent® (dupilumab) Approved in the European Union as the First and Only Medicine for Young Children with Eosinophilic Esophagitis

GlobeNewswire

17 days ago

Dupixent® (dupilumab) Approved in the European Union as the First and Only Medicine for Young Children with Eosinophilic Esophagitis

MT Newswires

18 days ago

Regeneron Pharmaceuticals Insider Sold Shares Worth $844,610, According to a Recent SEC Filing

Is Weakness In Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?

Simply Wall St.

18 days ago

Is Weakness In Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?

Regeneron price target lowered to $1,126 from $1,137 at Truist

TipRanks

21 days ago

Regeneron price target lowered to $1,126 from $1,137 at Truist

MT Newswires

22 days ago

UBS Cuts Price Target on Regeneron Pharmaceuticals to $1,130 From $1,251, Maintains Buy Rating

What Makes Regeneron Pharmaceuticals (REGN) an Attractive Investment Opportunity?

Insider Monkey

22 days ago

What Makes Regeneron Pharmaceuticals (REGN) an Attractive Investment Opportunity?

MT Newswires

22 days ago

Leerink Partners Adjusts Price Target on Regeneron Pharmaceuticals to $880 From $1,077

MT Newswires

22 days ago

Bernstein Adjusts Price Target on Regeneron Pharmaceuticals to $1,110 From $1,135

MT Newswires

22 days ago

Evercore ISI Adjusts Price Target on Regeneron Pharmaceuticals to $1,170 From $1,175, Maintains Outperform Rating

MT Newswires

22 days ago

BMO Capital Adjusts Price Target on Regeneron Pharmaceuticals to $1,190 From $1,300, Maintains Outperform Rating

MT Newswires

22 days ago

Morgan Stanley Adjusts Price Target on Regeneron Pharmaceuticals to $1,184 From $1,235, Maintains Overweight Rating

MT Newswires

22 days ago

Piper Sandler Adjusts Price Target on Regeneron Pharmaceuticals to $1,195 From $1,242, Maintains Overweight Rating

MT Newswires

22 days ago

Barclays Adjusts Price Target on Regeneron Pharmaceuticals to $1,065 From $1,080, Maintains Overweight Rating

Decoding Regeneron Pharmaceuticals Inc (REGN): A Strategic SWOT Insight

GuruFocus.com

22 days ago

Decoding Regeneron Pharmaceuticals Inc (REGN): A Strategic SWOT Insight

Morningstar Research

23 days ago

Analyst Report: Regeneron Pharmaceuticals, Inc.

MT Newswires

23 days ago

Oppenheimer Cuts Regeneron Pharmaceuticals Price Target to $1,150 From $1,1200

MT Newswires

23 days ago

RBC Lowers Price Target on Regeneron Pharmaceuticals to $1,215 From $1,260

Why Is Regeneron Pharmaceuticals Stock Trading Lower Today?

Benzinga

23 days ago

Why Is Regeneron Pharmaceuticals Stock Trading Lower Today?

HRMY vs. REGN: Which Stock Is the Better Value Option?

Zacks

23 days ago

HRMY vs. REGN: Which Stock Is the Better Value Option?

Regeneron Takes A Ghastly Turn As High-Dose Eylea Lags And Biosimilars Loom

Investor's Business Daily

23 days ago

Regeneron Takes A Ghastly Turn As High-Dose Eylea Lags And Biosimilars Loom

Regeneron (REGN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

Zacks

23 days ago

Regeneron (REGN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

REGN Q3 Earnings and Revenues Beat on Strong Eylea HD & Dupixent Sales

Zacks

23 days ago

REGN Q3 Earnings and Revenues Beat on Strong Eylea HD & Dupixent Sales

Regeneron (REGN) Tops Q3 Earnings and Revenue Estimates

Zacks

23 days ago

Regeneron (REGN) Tops Q3 Earnings and Revenue Estimates

Regeneron beats results estimates on demand for eczema treatment, eye drug

Reuters

23 days ago

Regeneron beats results estimates on demand for eczema treatment, eye drug

MT Newswires

23 days ago

Regeneron Pharmaceuticals' Q3 Adjusted Net Income, Revenue Rises

Associated Press Finance

23 days ago

Regeneron: Q3 Earnings Snapshot

Regeneron Reports Third Quarter 2024 Financial and Operating Results

GlobeNewswire

23 days ago

Regeneron Reports Third Quarter 2024 Financial and Operating Results

Regeneron to Report Q3 Earnings: What's in the Offing?

Zacks

a month ago

Regeneron to Report Q3 Earnings: What's in the Offing?

EyePoint's Investigational Drug Shows Early And Sustained Improvement Than Regeneron's Eylea For Diabetes-Associated Vision Loss

Benzinga

a month ago

EyePoint's Investigational Drug Shows Early And Sustained Improvement Than Regeneron's Eylea For Diabetes-Associated Vision Loss

Illumina (ILMN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Zacks

a month ago

Illumina (ILMN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Unlocking Q3 Potential of Regeneron (REGN): Exploring Wall Street Estimates for Key Metrics

Zacks

a month ago

Unlocking Q3 Potential of Regeneron (REGN): Exploring Wall Street Estimates for Key Metrics

MT Newswires

a month ago

Bernstein Adjusts Price Target on Regeneron Pharmaceuticals to $1,135 From $1,210, Maintains Outperform Rating

Stock-Split Watch: 2 Healthcare Stocks That Look Ready to Split

Motley Fool

a month ago

Stock-Split Watch: 2 Healthcare Stocks That Look Ready to Split

Possible Bearish Signals With Regeneron Pharmaceuticals Insiders Disposing Stock

Simply Wall St.

a month ago

Possible Bearish Signals With Regeneron Pharmaceuticals Insiders Disposing Stock

Sanofi Eyes Breakout After Pharma Titan Rides Vaccine Sales To Quarterly Beat

Investor's Business Daily

a month ago

Sanofi Eyes Breakout After Pharma Titan Rides Vaccine Sales To Quarterly Beat

Eli Lilly's Newly FDA-Approved Eczema Drug Improves Skin And Itch In Patients Previously Treated With Sanofi/Regeneron's Dupixent

Benzinga

a month ago

Eli Lilly's Newly FDA-Approved Eczema Drug Improves Skin And Itch In Patients Previously Treated With Sanofi/Regeneron's Dupixent

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Zacks

a month ago

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

MT Newswires

a month ago

Regeneron, Sanofi Report Dupixent 'Significantly' Reduced Itch, Hive Activity in Phase 3 Study for CSU

MT Newswires

a month ago

JPMorgan Adjusts Price Target on Regeneron Pharmaceuticals to $1,150 From $1,200

MT Newswires

a month ago

Evercore ISI Adjusts Price Target on Regeneron Pharmaceuticals to $1,175 From $1,250

Regeneron (REGN) Earnings Expected to Grow: Should You Buy?

Zacks

a month ago

Regeneron (REGN) Earnings Expected to Grow: Should You Buy?

Dupixent® (dupilumab) Late-Breaking Positive Phase 3 Data in Chronic Spontaneous Urticaria to Be Presented at ACAAI

GlobeNewswire

a month ago

Dupixent® (dupilumab) Late-Breaking Positive Phase 3 Data in Chronic Spontaneous Urticaria to Be Presented at ACAAI

The Zacks Analyst Blog Highlights Novo Nordisk, Novartis, Pfizer, Regeneron and Biogen

Zacks

a month ago

The Zacks Analyst Blog Highlights Novo Nordisk, Novartis, Pfizer, Regeneron and Biogen

MT Newswires

a month ago

Barclays Adjusts Price Target on Regeneron Pharmaceuticals to $1,080 From $1,220

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Zacks

a month ago

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Amgen plans launch of Eylea biosimilar after court ruling

BioPharma Dive

a month ago

Amgen plans launch of Eylea biosimilar after court ruling

The Zacks Analyst Blog Highlights Novo Nordisk, Novartis, Pfizer, Regeneron Pharmaceuticals and Biogen

Zacks

a month ago

The Zacks Analyst Blog Highlights Novo Nordisk, Novartis, Pfizer, Regeneron Pharmaceuticals and Biogen

MT Newswires

a month ago

Update: Amgen to Launch Biosimilar of Eylea After Court Denies Regeneron's Stay Request

MT Newswires

a month ago

Market Chatter: Amgen to Launch Biosimilar of Eylea After Court Denies Regeneron's Stay Request

Morningstar Research

a month ago

Analyst Report: Regeneron Pharmaceuticals, Inc.

MT Newswires

a month ago

Wells Fargo Cuts Price Target on Regeneron Pharmaceuticals to $1,050 From $1,200

Regeneron Pharmaceuticals' (NASDAQ:REGN) earnings growth rate lags the 26% CAGR delivered to shareholders

Simply Wall St.

a month ago

Regeneron Pharmaceuticals' (NASDAQ:REGN) earnings growth rate lags the 26% CAGR delivered to shareholders

5 Large Drug Stocks Likely to Outpace Q3 Earnings Estimates

Zacks

a month ago

5 Large Drug Stocks Likely to Outpace Q3 Earnings Estimates

MT Newswires

a month ago

Regeneron Says Eylea HD Sustains Vision Gains in Diabetic Macular Edema in Extension Study

Regeneron announces three-year data for EYLEA HD Injection 8 mg study

TipRanks

a month ago

Regeneron announces three-year data for EYLEA HD Injection 8 mg study

Three-year Results for EYLEA HD® (aflibercept) Injection 8 mg Demonstrate Continued Durable Vision Gains and Anatomic Improvements with Extended Dosing Intervals in Patients with Diabetic Macular Edema

GlobeNewswire

a month ago

Three-year Results for EYLEA HD® (aflibercept) Injection 8 mg Demonstrate Continued Durable Vision Gains and Anatomic Improvements with Extended Dosing Intervals in Patients with Diabetic Macular Edema

MT Newswires

a month ago

Jefferies Adjusts Price Target on Regeneron Pharmaceuticals to $1,205 From $1,245

Regeneron price target lowered to $1,137 from $1,200 at Truist

TipRanks

a month ago

Regeneron price target lowered to $1,137 from $1,200 at Truist

MT Newswires

a month ago

Truist Securities Adjusts Price Target on Regeneron Pharmaceuticals to $1,137 From $1,200, Maintains Buy Rating

Is Regeneron Pharmaceuticals, Inc. (REGN) the Best High Growth NASDAQ Stock That is Profitable in 2024?

Insider Monkey

a month ago

Is Regeneron Pharmaceuticals, Inc. (REGN) the Best High Growth NASDAQ Stock That is Profitable in 2024?

MT Newswires

a month ago

Morgan Stanley Adjusts Price Target on Regeneron Pharmaceuticals to $1,235 From $1,247

Kodiak Counts on Tarcocimab Eye Disease Program Despite Setbacks

Zacks

a month ago

Kodiak Counts on Tarcocimab Eye Disease Program Despite Setbacks

Regeneron (REGN) Loses -11.32% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Zacks

a month ago

Regeneron (REGN) Loses -11.32% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Regeneron Gains 13.5% Year to date: How to Play the Stock?

Zacks

a month ago

Regeneron Gains 13.5% Year to date: How to Play the Stock?

Is Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) The Best Morgan Stanley Overweight & Quality Stock?

Insider Monkey

2 months ago

Is Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) The Best Morgan Stanley Overweight & Quality Stock?

Regeneron Pharmaceuticals, Inc. (REGN): A Buzzing AI Health Stock to Add to Your Portfolio

Insider Monkey

2 months ago

Regeneron Pharmaceuticals, Inc. (REGN): A Buzzing AI Health Stock to Add to Your Portfolio

Should You Buy the Dip on This Top Growth Stock?

Motley Fool

2 months ago

Should You Buy the Dip on This Top Growth Stock?

MT Newswires

2 months ago

Goldman Sachs Adjusts Price Target on Regeneron Pharmaceuticals to $1,294 From $1,292

MT Newswires

2 months ago

RBC Lifts Price Target on Regeneron Pharmaceuticals to $1,260 From $1,252, Keeps Outperform Rating

MT Newswires

2 months ago

Regeneron Pharmaceuticals Insider Sold Shares Worth $1,054,060, According to a Recent SEC Filing

Sanofi, Regeneron's Dupixent Gets FDA Approval for COPD

Zacks

2 months ago

Sanofi, Regeneron's Dupixent Gets FDA Approval for COPD

Regeneron, Sanofi announce Dupixent approval in China for patients with COPD

TipRanks

2 months ago

Regeneron, Sanofi announce Dupixent approval in China for patients with COPD

Jim Cramer on Regeneron Pharmaceuticals Inc. (REGN): ‘Leerink Analysts Downgraded Regeneron To A Market Perform Hold After A Negative Eylea 2mg Biosimilar Preliminary Injunction Ruling’

Insider Monkey

2 months ago

Jim Cramer on Regeneron Pharmaceuticals Inc. (REGN): ‘Leerink Analysts Downgraded Regeneron To A Market Perform Hold After A Negative Eylea 2mg Biosimilar Preliminary Injunction Ruling’

Regeneron-Sanofi Drug Wins FDA Approval To Treat COPD

Investopedia

2 months ago

Regeneron-Sanofi Drug Wins FDA Approval To Treat COPD

Regeneron Shares Head for Worst Month Since 2019 on Legal Ruling

Bloomberg

2 months ago

Regeneron Shares Head for Worst Month Since 2019 on Legal Ruling

Share on Social Networks: